Literature DB >> 2380091

The incidence of myelitis after irradiation of the cervical spinal cord.

R B Marcus1, R R Million.   

Abstract

To further define the tolerance of the cervical spinal cord, the dose of radiation to the cervical spinal cord was calculated for all 2901 patients with malignancies of the upper respiratory tract treated at the University of Florida between October 1964 and December 1987. To further define the population evaluated, certain criteria were used: (a) a minimum of 3000 cGy to at least 2 cm of cervical spinal cord and (b) a minimum of 1 year of follow-up, unless a neurological complication occurred before 1 year. A total of 1112 patients were evaluable, of which 2 (0.18%) developed radiation myelitis. One received 4658 cGy to the cervical cord at 172.5 cGy per day, and the other patient received 4907 cGy to the cord at 169.2 cGy per day. The risk of myelitis at each dose level was 0/124 at 3000-3999 cGy, 0/442 at 4000-4499 cGy, 2/471 at 4500-4999 cGy, and 0/75 at a cord dose of 5000 cGy or greater.

Entities:  

Mesh:

Year:  1990        PMID: 2380091     DOI: 10.1016/0360-3016(90)90126-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  29 in total

Review 1.  Radiation therapy and the management of intramedullary spinal cord tumors.

Authors:  S R Isaacson
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Treatment related myelitis in Hodgkin's lymphoma following stem cell transplant, chemotherapy and radiation: a case report and review of the literature.

Authors:  Heather Gatcombe; Josh Lawson; Surasak Phuphanich; Ian Crocker
Journal:  J Neurooncol       Date:  2006-04-15       Impact factor: 4.130

Review 3.  Prognostic factors in intramedullary astrocytomas: a literature review.

Authors:  Vladimír Benes; Pavel Barsa; Vladimír Benes; Petr Suchomel
Journal:  Eur Spine J       Date:  2009-06-28       Impact factor: 3.134

Review 4.  The use of radiation in the management of spinal metastases.

Authors:  C M Faul; J C Flickinger
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

5.  Post-radiotherapy myelitis observed in an AIDS patient with a meningioma: case report and review of the literature.

Authors:  M Zeng; J Knisely
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

Review 6.  Updates in the management of intradural spinal cord tumors: a radiation oncology focus.

Authors:  Rupesh Kotecha; Minesh P Mehta; Eric L Chang; Paul D Brown; John H Suh; Simon S Lo; Sunit Das; Haider H Samawi; Julia Keith; James Perry; Arjun Sahgal
Journal:  Neuro Oncol       Date:  2019-06-10       Impact factor: 12.300

7.  Results of posterior surgery with intraoperative radiotherapy for spinal metastases.

Authors:  Taku Saito; Taiji Kondo; Takahiro Hozumi; Katsuyuki Karasawa; Atsushi Seichi; Kozo Nakamura
Journal:  Eur Spine J       Date:  2005-08-13       Impact factor: 3.134

8.  Phase II trial of chemotherapy, external and intraluminal radiation plus surgery for oesophageal cancer.

Authors:  J J Beitler; S Wadler; H Haynes; S Fell; A Rozenblit; E Wolf; B A Levine
Journal:  Med Oncol       Date:  1995-06       Impact factor: 3.064

9.  Whole-brain radiotherapy combined with surgery or stereotactic radiotherapy in patients with brain oligometastases: long-term analysis.

Authors:  Giuseppe Roberto D'Agostino; Rosa Autorino; Angelo Pompucci; Maria Carmen De Santis; Stefania Manfrida; Giuseppe Di Lella; Giovanna Mantini; Vincenzo Frascino; Silvia Chiesa; Alessio Albanese; Nicola Dinapoli; Luigi Azario; Alba Fiorentino; Vincenzo Valentini; Carmelo Anile; Mario Balducci
Journal:  Strahlenther Onkol       Date:  2011-06-28       Impact factor: 3.621

10.  Lhermitte sign and myelopathy after irradiation of the cervical spinal cord in radiotherapy treatment of head and neck cancer.

Authors:  V E M Mul; J M A de Jong; L H P Murrer; P L A van den Ende; R M A Houben; M Lacko; P Lambin; B G Baumert
Journal:  Strahlenther Onkol       Date:  2011-12-23       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.